Novo Nordisk Revives Iconic Ad Style for Ozempic
In a nostalgic twist on pharmaceutical marketing, Novo Nordisk is launching a fresh direct-to-consumer campaign for Ozempic, drawing inspiration from Apple’s memorable “Get a Mac” ads that aired between 2006 and 2010. The new campaign, titled “There’s Only One Ozempic”, brings back actors Justin Long and John Hodgman—famous for portraying the cool Mac and the bumbling PC—to represent Ozempic and its competitors, respectively.
The campaign aims to cut through the noise surrounding GLP-1 medications for Type 2 diabetes by spotlighting Ozempic’s unique FDA-approved indications. In the ads, Long portrays Ozempic, while Hodgman plays a composite of other GLP-1 brands and compounded semaglutide medications.
A Familiar Duo in a New Role
Neither Long nor Hodgman uses Ozempic, but their chemistry and history make them ideal for this creative reboot. The campaign features episodic clips that will run through the end of 2026 across social media platforms and connected TV, according to a Novo Nordisk spokesperson. Scenes range from office banter at a water cooler to a mock game show titled “GLP-1 Trivia.”
One of the ads humorously notes that it’s been exactly 8,476,092 minutes since the last time the duo appeared together on screen. While the comedic tone is strong, the message is clear: Ozempic stands out among its peers due to its multiple FDA-approved uses. These include improving blood sugar control and reducing the risks of major cardiovascular events and worsening chronic kidney disease in adults with Type 2 diabetes.
Clear Messaging in a Crowded Market
To ensure clarity during the ads’ major statement segments—a common subject of FDA scrutiny in pharma advertising—the campaign takes a minimalist approach. The required safety information is presented on a plain background, with Long reading directly from a music stand. This tactic aims to avoid distracting visuals that could detract from the essential medical disclaimers.
Each spot also features the catchy jingle, “There’s only one Ozempic,” set to the tune of Pilot’s 1974 hit “Magic.” This musical callback builds on the brand’s previous success with the “Oh, oh, oh, Ozempic” earworm, continuing the theme of memorable audio branding.
Clarifying Common Misconceptions
The campaign is Novo Nordisk’s response to growing confusion around GLP-1 medications. With Ozempic increasingly used as a catch-all term for the entire drug class, and compounded versions of semaglutide entering the market, the company is seeking to reaffirm Ozempic’s distinct positioning.
“There’s too much misinformation and miscommunication in our world today,” said Ed Cinca, Novo Nordisk’s senior vice president of marketing and patient solutions. “People with Type 2 diabetes deserve information that’s simple, accurate and useful when they’re seeking care.”
Cinca emphasized that not all GLP-1 medicines are the same. “Ozempic is differentiated by its multiple FDA-approved indications for adults with Type 2 diabetes, including those who also have cardiovascular disease and chronic kidney disease,” he added. The campaign is designed to educate patients and healthcare providers so they can have informed conversations about treatment options.
Strategic Marketing with a Patient-Centered Focus
Novo Nordisk’s strategy reflects a broader industry trend toward more patient-centric advertising. By leveraging familiar faces and a nostalgic format, the company hopes to make its message more relatable and memorable. The campaign aims to reach a wide audience, from long-time diabetes patients to those newly diagnosed, by presenting complex medical information in a lighthearted yet informative manner.
“Outcomes matter, clinical evidence matters, indications matter,” Cinca concluded. “At Novo Nordisk, our aim is to put patients at the center of care and to make sure they know there is only one Ozempic, which is only manufactured by Novo Nordisk.”
This article is inspired by content from Original Source. It has been rephrased for originality. Images are credited to the original source.